Full Breakdown
Yeast Engineered to Produce Cancer Drug Vinblastine at Near-Industrial Scale
8/13/2026, 10:38:10 PM
Core Development: Yeast Platform for Vinblastine Precursors
A research team led by Professor Lian Jiazhang at Zhejiang University (ZJU) engineered brewer’s yeast to synthesize catharanthine, the direct precursor to the anticancer drug vinblastine. The engineered strain generated 164.9 milligrams per litre of catharanthine in fermenters, a yield nearly 1,000 times higher than any previously reported global figure. The results were published in *Science* on July 16. The work built on a 2022 effort that first inserted the 30-step vinblastine synthesis pathway into yeast, which had initially produced only microgram-level outputs.
Background: Scarcity of Traditional Vinblastine Sources
Vinblastine has historically been extracted exclusively from the Madagascar periwinkle (*Catharanthus roseus*). Harvesting requires up to 2 tonnes of dried leaves to obtain 1 gram of the drug, making it more expensive than gold by weight and limiting reliable supply for decades. This scarcity has constrained treatment availability and driven high costs for patients worldwide.
Production Gains and Technical Details
The breakthrough resulted from addressing instability of a key intermediate within the yeast’s internal cellular structure. By stabilizing this step, the team achieved the reported 164.9 mg/L catharanthine concentration. The project involved collaboration with Qu Yang’s research group at the University of New Brunswick in Canada and Wang Yajie’s team at Westlake University, combining expertise in synthetic biology, metabolic engineering, and plant-derived alkaloid pathways.
Potential Impact on Cancer Treatment Access
If the yeast-based process can be scaled commercially, it could dramatically lower the cost of vinblastine production and reduce dependence on the labor-intensive periwinkle harvest. Greater supply stability may improve access to vinblastine-based chemotherapy regimens, particularly in low-resource settings where current pricing limits treatment options. Further development will focus on optimizing fermentation conditions and integrating downstream conversion of catharanthine to the final drug.
